• Shanghai HeartCare guided for H1 ended June 30, 2026 revenue of at least RMB 280 million, up at least 50.9% from RMB 185.5 million.
• Net profit expected at least RMB 60 million, versus RMB 50.9 million a year earlier; adjusted net profit seen at least RMB 70 million, up at least 104.7% from RMB 34.2 million.
• Forecast tied to higher product recognition, wider hospital coverage, stronger demand across ischemic stroke, hemorrhagic stroke, vascular closure lines.
• Adjusted profit outlook reflects richer mix of high-margin products, improved gross margin, tighter control of selling, distribution, administrative costs.
• Figures based on unaudited management accounts; interim results expected by end-August 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260721-12251530), on July 21, 2026, and is solely responsible for the information contained therein.